• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Hypotension - Pipeline Review, H2 2012 Product Image

Hypotension - Pipeline Review, H2 2012

  • Published: September 2012
  • 73 pages
  • Global Markets Direct

Hypotension – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Hypotension - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Hypotension, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hypotension. Hypotension - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Hypotension.
- A review of the Hypotension products under development by companies and universities/research institutes based on information derived from READ MORE >

2
List of Tables 5
List of Figures 5
Introduction 6
REPORT COVERAGE 6
Hypotension Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Hypotension 8
Hypotension Therapeutics under Development by Companies 10
Hypotension Therapeutics under Investigation by Universities/Institutes 11
Late Stage Products 12
Comparative Analysis 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Early Clinical Stage Products 14
Comparative Analysis 14
Hypotension Therapeutics – Products under Development by Companies 15
Hypotension Therapeutics – Products under Investigation by Universities/Institutes 16
Companies Involved in Hypotension Therapeutics Development 17
Medinox, Inc. 17
Sangart, Inc. 18
Chelsea Therapeutics, Inc. 19
Ferring Pharmaceuticals, Inc. 20
Hypotension – Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Combination Products 22
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
selepressin - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
droxidopa - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
droxidopa - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
NOX-100 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
hydrocortisone acetate - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
MP4-OX - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Atomoxetine + Acarbose + Pyridostigmine Bromide + Yohimbine + Midodrine + Modafinil + Octreotide + Diphenhydramine Hydrochloride + Ranitidine + Tranylcypromine + Ergotamine + Celecoxib + Pseudoephedrine + Methylphenidate + Indomethacin + Ibuprofen + Oxymetazoline + Acetazolamide + Rivastigmine tartrate + Carbidopa - Drug Profile 37
Product Description 37
Mechanism of Action 38
R&D Progress 40
Droxidopa + Alpha-Methyldopa + Carbidopa + Metyrosine + Levodopa + Atomoxetine + Metoclopramide - Drug Profile 41
Product Description 41
Mechanism of Action 42
R&D Progress 42
metaraminol - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
midodrine - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
droxidopa - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
droxidopa - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Hypotension Therapeutics – Drug Profile Updates 47
Hypotension Therapeutics – Discontinued Products 58
Hypotension Therapeutics - Dormant Products 59
Hypotension – Product Development Milestones 60
Featured News & Press Releases 60
Jun 21, 2012: Chelsea Therapeutics Announces Results From Two Phase III Studies Of Northera In Patients With Neurogenic OH 60
May 22, 2012: Chelsea Therapeutics Completes End-of-Review Meeting With FDA For Northera Capsules New Drug Application 62
Apr 27, 2012: Chelsea To Present Results From Pivotal Northera Study At AAN Annual Meeting 63
Mar 29, 2012: Shire Reports FDA's Update On Midodrine HCl 64
Mar 28, 2012: Chelsea Receives Complete Response Letter From FDA For Northera Capsules 65
Feb 23, 2012: FDA Advisory Panel Recommends Approval Of Chelsea's NORTHERA To Treat Neurogenic Orthostatic Hypotension 66
Feb 21, 2012: Chelsea To Discuss NORTHERA NDA For Treatment Of Neurogenic Orthostatic Hypotension At FDA Advisory Committee Meeting 67
Feb 13, 2012: Chelsea Therapeutics's CEO To Review NORTHERA NDA And Provide Update On Upcoming Advisory Committee Meeting During Presentation At BIO CEO 67
Jan 03, 2012: Chelsea Therapeutics Announces FDA's Advisory Committee Meeting Date For Review Of NORTHERA NDA For Treatment Of Symptomatic Neurogenic Orthostatic Hypotension 70
Dec 15, 2011: Chelsea Therapeutics Receives Notice Of Allowance Of Key US Patent For Novel, Controlled Release Formulation Of Northera 70
Appendix 72
Methodology 72
Coverage 72
Secondary Research 72
Primary Research 72
Expert Panel Validation 72
Contact Us 73
Disclaimer 73

List of Tables
Number of Products Under Development for Hypotension, H2 2012 8
Products under Development for Hypotension – Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 10
Number of Products under Investigation by Universities/Institutes, H2 2012 11
Comparative Analysis by Late Stage Development, H2 2012 12
Comparative Analysis by Mid Clinical Stage Development, H2 2012 13
Comparative Analysis by Early Clinical Stage Development, H2 2012 14
Products under Development by Companies, H2 2012 15
Products under Investigation by Universities/Institutes, H2 2012 16
Medinox, Inc., H2 2012 17
Sangart, Inc., H2 2012 18
Chelsea Therapeutics, Inc., H2 2012 19
Ferring Pharmaceuticals, Inc., H2 2012 20
Assessment by Monotherapy Products, H2 2012 21
Assessment by Combination Products, H2 2012 22
Assessment by Stage and Route of Administration, H2 2012 24
Assessment by Stage and Molecule Type, H2 2012 26
Hypotension Therapeutics – Drug Profile Updates 47
Hypotension Therapeutics – Discontinued Products 58
Hypotension Therapeutics – Dormant Products 59

List of Figures
Number of Products under Development for Hypotension, H2 2012 8
Products under Development for Hypotension – Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Products under Investigation by Universities/Institutes, H2 2012 11
Late Stage Products, H2 2012 12
Mid Clinical Stage Products, H2 2012 13
Early Clinical Stage Products, H2 2012 14
Assessment by Monotherapy Products, H2 2012 21
Assessment by Combination Products, H2 2012 22
Assessment by Route of Administration, H2 2012 23
Assessment by Stage and Route of Administration, H2 2012 24
Assessment by Molecule Type, H2 2012 25
Assessment by Stage and Molecule Type, H2 2012 26

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos